Policy & Regulation
AstraZeneca provides update on the phase III EAGLE trial of Imfinzi
10 December 2018 - AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, along with MedImmune, its global biologics research and development arm, announced on Friday overall surv...
Millendo Therapeutics Inc closes merger agreement with OvaScience Inc
10 December 2018 - Biopharmaceutical company Millendo Therapeutics Inc (Nasdaq:MLND) revealed on Friday the completion of its merger agreement with OvaScience Inc following the approval of its stockho...
Tenax Therapeutics expects USD10m from underwritten offering of 5,181,346 units
10 December 2018 - Pharmaceutical company Tenax Therapeutics, Inc. (Nasdaq:TENX) said on Friday that it has priced its underwritten offering of 5,181,346 units at an offering price of USD1.93 per unit...
CStone Pharmaceuticals names new senior vice president, chief translational medicine officer
10 December 2018 - CStone Pharmaceuticals, a biopharma company focused on developing and commercialising innovative immuno-oncology and molecularly targeted drugs, announced today that it has named Ar...
Consortium led by CX Partners acquires equity ownership in Veeda Clinical Research Private
10 December 2018 - A consortium of private equity investors led by CX Partners Fund 2 Limited have acquired a significant equity ownership in Veeda Clinical Research Private Limited, an independent cl...
Cantargia reports on completion of phase I safety evaluation part of CANFOUR trial of antibody CAN04; Phase IIa part being initiated
10 December 2018 - Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Friday that all patients in the phase I part of...
Related Headlines

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

Genentech's Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People with HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Confo Therapeutics Appoints Landolt as its Chief Counsel Legal and Intellectual Property

SFA Therapeutics Wins US Patent for Use of Short Chain Fatty Acids in Cancer Prevention. New Treatment for Hepatitis B

Paraxel Collaborates with Eli Lilly to Develop China's Clinical Research Workforce

NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

European Medicines Agency Accepts Extension of Marketing Authorisation Application for Review of Celltrion's Remsima SC, the Subcutaneous Version of Remsima

Celltrion and Teva Announce FDA Approval of Truxima, a Biosimilar to Rituxan, for Three Non-Hodgkin's Lymphoma Indications

Celgene Posts Results of AUGMENT Evaluating Revlimid In Combination with Rituximab In Patients with Relapsed/Refractory Indolent Lymphoma

Celgene, Acceleron Pharma Present Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes

Bluebird bio and Celgene Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma

HydRx Farms receives new US Patent

Johnson & Johnson's Darzalex combined with lenalidomide and dexamethasone decreases disease progression risk in multiple myeloma study